AJKD：水飞蓟素或可治疗糖尿病肾病

　　Fallahzadeh等人近期发表在《美国肾脏病杂志》杂志上的一项研究发现一种新的潜在剂治疗糖尿病肾病：草药水飞蓟素。

　　糖尿病肾病是全世界糖尿病肾衰竭最常见的原因。Fallahzadeh和他的同事们研究了新的潜在剂治疗糖尿病肾病：草药水飞蓟素，具有抗氧化和抗发炎的特性。

　　研究人员进行了一项随机，双盲，安慰剂对照的临床试验，评估可能的疗效和安全性的水飞蓟素，除外运用RAS抑制剂的2型糖尿病患者和明显的肾病患者，对明显蛋白尿，少尿的患者进行随机分配，使用水飞蓟素。在随后的研讨中，研究人员发现使用植物产品，治疗疾病的难得机遇和特殊挑战。与传统的药物相比，植物通常是未知成分的混合物，必须特别注意所有潜在的活性成分的分析，以及批与批之间的变化。 

与糖尿病肾病相关的拓展阅读：

• AJKD：水飞蓟素或可治疗糖尿病肾病
• 减肥术提高糖尿病肾病缓解率
• Diabetes Care：食用豆奶未影响2型糖尿病肾病炎症和氧化应激
• 奥美沙坦加正清风痛宁降低高血压糖尿病肾病患者尿蛋白
• Diabetes:科学家从中药中发现治疗糖尿病肾病潜在药物
更多信息请点击：有关糖尿病肾病更多资讯

Silymarin: A Potential Treatment for Diabetic Nephropathy 

Diabetic nephropathy is the most common cause of kidney failure worldwide. In this month's AJKD, Fallahzadeh and colleagues investigate a new potential agent to treat diabetic nephropathy: silymarin, an herbal drug with antioxidant and anti-inflammatory properties. The authors performed a randomized, double-blind, placebo-controlled, clinical trial assessing the possible efficacy and safety of silymarin in addition to RAS inhibitors in patients with type 2 diabetes and overt nephropathy, demonstrating a significantly greater decrease in albuminuria in participants randomized to silymarin. In any accompanying editorial, Meyers and Briggs discuss both the valuable opportunities and unique challenges of using botanical products to treat diseases. The authors remind readers that, unlike conventional drugs, botanicals typically are mixtures of uncharacterized constituents, and particular attention must be placed on analysis of all potential active ingredients, as well as batch-to-batch variability—and, just as with many conventional agents, promising initial reports of botanical products often are not confirmed.